SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
| Qalsody | 6.7 mg/ml | Solution for injection · Intrathecal use | 1 Vial | SAR 98211.15 | NCE · Prescription | Biogen Idec B.V-Natherland | Valid |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
| QALSODY | 100MG/15ML (6.7MG/ML) | solution · intrathecal | BIOGEN MA | Prescription | 25 Apr 2023 |
EMA European Union — centrally authorised medicines
Qalsody Biogen Netherlands B.V. · Authorised · authorised 29 May 2024 · ATC N07XX22
Therapeutic indication (EMA)
Qalsody is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
| QALSODY | 02555735 | 100 MG / 15 ML | SOLUTION · INTRATHECAL | BIOGEN CANADA INC |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.